Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Total Revenue of $228.37 million for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $228.37M | -0.9% |
| 2024 | $230.47M | -2.2% |
| 2023 | $235.64M | +3.3% |
| 2022 | $228.03M | -9.9% |
| 2021 | $253.16M | +12.5% |
| 2020 | $225.11M | -17.3% |
| 2019 | $272.26M | +8.5% |
| 2018 | $250.99M | +806.6% |
| 2017 | $27.68M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.48M | -32.4% | +3.9% |
| June 30, 2025 | $52.44M | +11.4% | +14.0% |
| March 31, 2025 | $46.01M | +5.1% | -42.9% |
| September 30, 2024 | $80.54M | +43.5% | +71.1% |
| June 30, 2024 | $47.08M | -13.7% | +7.6% |
| March 31, 2024 | $43.77M | -17.1% | -22.0% |
| September 30, 2023 | $56.12M | -1.7% | +2.8% |
| June 30, 2023 | $54.57M | -8.3% | +3.4% |
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -0.9% in Total Revenue compared to the prior fiscal year.
- Over the 2017–2025 period, PUMA BIOTECHNOLOGY, INC.’s total revenue has grown by 724.9% (from $27.68 million to $228.37 million).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: